Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib Eye Drops Extension Study in Neovascular AMD
NCT00733304Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2008
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of pazopanib in neovascular age-related macular degeneration (NVAMD), sponsored by GSK. Started Jun 2008; status: completed.
02
Drugs
pazopanib
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00733304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00733304.